Donor immune cells take on tough leukemia in early trial
NCT ID NCT06326008
First seen Mar 15, 2026 · Last updated Jun 20, 2026 · Updated 10 times
Summary
This early-phase trial tests a two-step approach for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. First, patients receive donor-derived CD19 CAR T cells, then a stem cell transplant from the same donor, followed by donor-derived CD22 CAR T cells. The goal is to see if this combination is safe and tolerable. About 48 participants will be enrolled to assess side effects and begin to look at how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor-derived CD19 and CD22 CAR T cells
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat B-cell acute lymphoblastic leukemia who have run out of standard therapies.
What could go wrong
This is a very early phase 1 trial with only 48 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects from the CAR T cells and stem cell transplant, including graft-versus-host disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.